




Shri Yashwantrao Bhonsale Education Society's

YASHWANTRAO BHONSALE COLLEGE OF PHARMACY

Heartiest Congratulations!!!

For publishing a review article entitled

“Understanding the Chemistry & Pharmacology of Antibody-Drug Conjugates in Triple- Negative Breast Cancer with special reference to Exatecan derivatives”



IF: 2.8

in
Medical Oncology

Indexed in:

SCOPUS, SCIE, UGC-CARE LIST (INDIA)

**SPRINGER
NATURE**



YBCP Authors



Ms. Sanjana Sawant
PG Pharmaceutical Chemistry



Dr. Gaurav Gopal Naik
Associate Professor,
PG Pharmaceutical Chemistry



Dr. Vijay A. Jagtap
Principal



**BHONSALE
KNOWLEDGE
CITY**

Charthe, Vazarwadi,
Sawantwadi. Dist.Sondhudurg. 416 510
Phone : 02363-273535/273456



/sybespharmacy



/ypharmacy



/ypharmacy



/yashwantraobhonsalecop



/ypharmacy



Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives

Sanjana Sawant¹ · Gaurav Gopal Naik¹ · Alakh N. Sahu² · Vijay A. Jagtap¹


Received: 5 September 2024 / Accepted: 15 October 2024

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024

Abstract

In the spectrum of breast malignancies, triple-negative breast cancer is the most widely spreading subtype of breast cancer due to a low availability of therapeutic remedies. Recently, antibody–drug conjugates dramatically resolved the landscape for the treatment of triple-negative breast cancer. This review mainly focuses on the chemistry, structure, mechanism of action, and role of antibody–drug conjugates in triple-negative breast cancer. Datopotecan Deruxtecan (Dato-DXd) is a new-generation ADC showing encouraging results for TNBC. In this review, we have also emphasized TROP-2-directed Datopotamab deruxtecan ADCs to treat triple-negative breast cancer, its synthesis, mechanism of action, pharmacokinetics, pharmacodynamics, adverse events, and their ongoing clinical trials.

Graphical abstract



Keywords Triple-negative breast cancer · Antibody–drug conjugates · Clinical trials · Datopotamab deruxtecan · Payloads

Extended author information available on the last page of the article